KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Long-Term Deferred Tax (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 15 years of Long-Term Deferred Tax data on record, last reported at $3.8 billion in Q3 2025.

  • For Q3 2025, Long-Term Deferred Tax rose 27.58% year-over-year to $3.8 billion; the TTM value through Sep 2025 reached $3.8 billion, up 27.58%, while the annual FY2024 figure was $3.3 billion, 28.68% up from the prior year.
  • Long-Term Deferred Tax reached $3.8 billion in Q3 2025 per REGN's latest filing, up from $3.6 billion in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $3.8 billion in Q3 2025 and bottomed at $723.2 million in Q3 2021.
  • Average Long-Term Deferred Tax over 5 years is $2.2 billion, with a median of $2.2 billion recorded in 2023.
  • Peak YoY movement for Long-Term Deferred Tax: dropped 10.07% in 2021, then skyrocketed 100.79% in 2022.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $723.2 million in 2021, then surged by 138.34% to $1.7 billion in 2022, then surged by 49.41% to $2.6 billion in 2023, then grew by 28.68% to $3.3 billion in 2024, then increased by 16.07% to $3.8 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Deferred Tax were $3.8 billion in Q3 2025, $3.6 billion in Q2 2025, and $3.4 billion in Q1 2025.